[go: up one dir, main page]

MA34457B1 - Combinaison d'un composé glyt1 avec des agents antipsychotiques - Google Patents

Combinaison d'un composé glyt1 avec des agents antipsychotiques

Info

Publication number
MA34457B1
MA34457B1 MA35645A MA35645A MA34457B1 MA 34457 B1 MA34457 B1 MA 34457B1 MA 35645 A MA35645 A MA 35645A MA 35645 A MA35645 A MA 35645A MA 34457 B1 MA34457 B1 MA 34457B1
Authority
MA
Morocco
Prior art keywords
combination
glyt1
compound
antipsychotic agents
schizophrenia
Prior art date
Application number
MA35645A
Other languages
English (en)
French (fr)
Inventor
Joseph G Wettstein
Daniela Alberati
Jean-Luc Moreau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34457(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34457B1 publication Critical patent/MA34457B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA35645A 2010-08-09 2011-08-05 Combinaison d'un composé glyt1 avec des agents antipsychotiques MA34457B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09
PCT/EP2011/063533 WO2012019970A1 (en) 2010-08-09 2011-08-05 Combination of glyt1 compound with antipsychotics

Publications (1)

Publication Number Publication Date
MA34457B1 true MA34457B1 (fr) 2013-08-01

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35645A MA34457B1 (fr) 2010-08-09 2011-08-05 Combinaison d'un composé glyt1 avec des agents antipsychotiques

Country Status (29)

Country Link
US (1) US20120035156A1 (es)
EP (1) EP2603219B1 (es)
JP (1) JP2013533297A (es)
KR (1) KR101455947B1 (es)
CN (1) CN103068388A (es)
AR (1) AR084401A1 (es)
AU (1) AU2011288536B2 (es)
BR (1) BR112013003068A2 (es)
CA (1) CA2803656A1 (es)
CL (1) CL2013000378A1 (es)
CR (1) CR20130027A (es)
CY (1) CY1115886T1 (es)
DK (1) DK2603219T3 (es)
EA (1) EA201291477A1 (es)
EC (1) ECSP13012431A (es)
ES (1) ES2521596T3 (es)
HR (1) HRP20141199T1 (es)
MA (1) MA34457B1 (es)
MX (1) MX2013001166A (es)
NZ (1) NZ604891A (es)
PE (1) PE20131100A1 (es)
PH (1) PH12013500078A1 (es)
PL (1) PL2603219T3 (es)
PT (1) PT2603219E (es)
SG (1) SG187108A1 (es)
SI (1) SI2603219T1 (es)
TW (1) TW201211019A (es)
WO (1) WO2012019970A1 (es)
ZA (1) ZA201300434B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2753632T (pt) 2011-09-08 2023-08-17 Sage Therapeutics Inc Esteróides neuroactivos, composições e respectivas utilizações
SMT202500336T1 (it) 2013-03-13 2025-11-10 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
MX2016006742A (es) * 2013-12-03 2016-08-12 Hoffmann La Roche Composicion farmaceutica.
SG11201607166XA (en) * 2014-04-30 2016-09-29 Yufeng Jane Tseng Use of known compounds as d-amino acid oxidase inhibitors
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN112121171A (zh) * 2014-10-07 2020-12-25 萨奇治疗股份有限公司 神经活性化合物及其使用方法
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
CN113292623A (zh) 2015-07-06 2021-08-24 萨奇治疗股份有限公司 孕甾醇及其使用方法
AU2016289971C1 (en) 2015-07-06 2022-12-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP7112331B2 (ja) 2016-04-01 2022-08-03 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
TWI752976B (zh) 2016-07-07 2022-01-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN115322238A (zh) 2016-10-18 2022-11-11 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
KR102739607B1 (ko) * 2017-11-14 2024-12-06 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물
CN116212025B (zh) * 2020-01-09 2025-08-05 迪斯克医药公司 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1656361T3 (da) * 2003-08-11 2008-05-05 Hoffmann La Roche Piperazin med OR-substitueret phenylgruppe og anvendelse deraf som GLYT1-inhibitorer
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
NZ563238A (en) * 2005-04-08 2011-01-28 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
CN101479243B (zh) * 2006-06-28 2013-01-02 安姆根有限公司 甘氨酸转运子-1抑制剂

Also Published As

Publication number Publication date
PL2603219T3 (pl) 2015-03-31
AU2011288536B2 (en) 2014-10-09
CN103068388A (zh) 2013-04-24
AU2011288536A1 (en) 2013-01-31
AR084401A1 (es) 2013-05-15
CA2803656A1 (en) 2012-02-16
EP2603219A1 (en) 2013-06-19
PH12013500078A1 (en) 2013-03-11
PT2603219E (pt) 2014-11-25
MX2013001166A (es) 2013-03-22
SG187108A1 (en) 2013-02-28
EP2603219B1 (en) 2014-09-17
KR101455947B1 (ko) 2014-10-28
PE20131100A1 (es) 2013-09-23
SI2603219T1 (sl) 2014-12-31
JP2013533297A (ja) 2013-08-22
WO2012019970A1 (en) 2012-02-16
KR20130045379A (ko) 2013-05-03
US20120035156A1 (en) 2012-02-09
ZA201300434B (en) 2013-09-25
ECSP13012431A (es) 2013-03-28
TW201211019A (en) 2012-03-16
HRP20141199T1 (hr) 2015-02-13
ES2521596T3 (es) 2014-11-13
NZ604891A (en) 2015-01-30
CR20130027A (es) 2013-03-04
BR112013003068A2 (pt) 2016-06-28
EA201291477A1 (ru) 2013-06-28
DK2603219T3 (da) 2014-10-13
CL2013000378A1 (es) 2013-05-03
CY1115886T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
MA34457B1 (fr) Combinaison d'un composé glyt1 avec des agents antipsychotiques
MA37740A1 (fr) Seringue
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
JO3116B1 (ar) مشتق بيرازولوكينولين كمثبطات ل pde9
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
CY1111269T1 (el) Ρυθμιστες βενζιμιδαζολης του vr1
MX2015011778A (es) Combinacion de farmaco.
MA39172A1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MY163083A (en) Solid forms of a pharmaceutically active substance
IN2015DN00185A (es)
MX2009009552A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
EA201270216A1 (ru) Фармацевтический состав
MA38096B1 (fr) Solutions mydriatiques et anti-inflammatoires stables sans agents de conservation destinees a etre injectees
ECSP12011880A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
EA201270590A1 (ru) Ингибиторы акт
MA35043B1 (fr) Formulation pharmaceutique comprenant de l'inositol
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
JO3192B1 (ar) مركب بنزوثيازولون
MA42166B1 (fr) Seringue
MA34709B1 (fr) Compositions pharmaceutiques
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη
NI201000139A (es) ASOCIACION DE UN INHIBIDOR DE CORRIENTE SINUSAL If Y DE UN BETA-BLOQUEANTE